Rein Therapeutics plans Phase 2 UK trial for LTI-03

Rhea-AI Filing Summary

FAQ

8-K Event Classification

What did Rein Therapeutics (RNTX) disclose in this 8-K?

What is the subject of Rein Therapeutics' press release mentioned in the 8-K?

Which exhibit did Rein Therapeutics (RNTX) file with this 8-K?

Does this 8-K from Rein Therapeutics include financial statements?

Where can investors find details about the LTI-03 Phase 2 trial for Rein Therapeutics?

Accepted by SEC EDGAR 08/19/2025 - 08:06 AM EDT

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rein Therapeutics, Inc. reported that it issued a press release about the planned Phase 2 clinical trial of its LTI-03 product candidate in the U.K. The company used this report to formally note the communication to the market and attached the press release as an exhibit for investors to review.

The filing does not provide clinical, financial, or operational details about the Phase 2 trial itself, but directs readers to the full press release, dated August 19, 2025, for more information on the LTI-03 development plans.

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Rein Therapeutics disclosed that it issued a press release about the planned Phase 2 clinical trial of its LTI-03 product candidate in the U.K., and filed that release as an exhibit.

The press release concerns the planned Phase 2 clinical trial of Rein Therapeutics' LTI-03 product candidate in the U.K.

Rein Therapeutics filed Exhibit 99.1, which is the company’s press release dated August 19, 2025, along with Exhibit 104, the cover page interactive data file.

No, this report only lists exhibits and notes a press release about a planned Phase 2 trial; it does not include financial statements.

REIN THERAPEUTICS, INC.

Dated: August 19, 2025

/s/ Brian Windsor

Brian Windsor, Ph.D.,

President and Chief Executive Officer

Details are provided in Rein Therapeutics’ press release dated August 19, 2025, which is attached to the report as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 19, 2025

REIN THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-38130

13-4196017

(State or Other Jurisdiction
of Incorporation)

(Commission

File Number)

(I.R.S. Employer
Identification Number)

12407 N. Mopac Expy., Suite 250, #390

Austin, Texas 78758

(Address of principal executive offices)

(737) 802-1989

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock: Par value $.001	RNTX	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 19, 2025, Rein Therapeutics, Inc. issued a press release concerning the planned Phase 2 clinical trial of its LTI-03 product candidate in the U.K. A copy of the press release is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed with this report:


Exhibit 99.1		The Company’s press release dated August 19, 2025

Exhibit 104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR